Medicenna Therapeutics Corp. MDNAF
0.31 USD -0.01 (-1.59%)
At closeNov 3, 2026, 4:00 PM EST
0.304 Day range 0.305
0.229 52-week range 1.30
- YTD
- -54.14%
- 1 year
- -70.75%
- Market cap
- 28.61M
- EPS (ttm)
- -0.16
- YTD return
- -54.14%
- 1-year return
- -70.75%
- Volume
- 5.50K
- Avg volume
- 43.19K
- Open
- 0.304
- Previous close
- 0.315
- Day's range
- 0.304 – 0.305
- 52-week range
- 0.229 – 1.30
2Y -1.3900 (-81.76%)
Financials — quick view
MDNAF Revenue — quarterly 0
MDNAF Net income — quarterly -2.86M
MDNAF EPS — quarterly -0.04
News
Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders 
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease 
Medicenna Announces Results of Annual General and Special Meeting of Shareholders 
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting 
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences 
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights 
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms 
Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026 
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs 
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
Your note
Sign in to keep a note on MDNAF — it syncs with the Stock Master app.